Literature DB >> 34074601

OTULIN in NF-κB signaling, cell death, and disease.

Lien Verboom1, Esther Hoste1, Geert van Loo2.   

Abstract

Tight control of inflammatory signaling pathways is an absolute requirement to avoid chronic inflammation and disease. One of the proteins responsible for such control is OTU deubiquitinase with linear linkage specificity (OTULIN), the only mammalian deubiquitinating enzyme (DUB) exclusively hydrolyzing linear ubiquitin chains from proteins modified by the linear ubiquitin chain assembly complex (LUBAC) described thus far. Recent findings show that loss-of-function mutations in OTULIN underlie a severe early-onset human autoinflammatory disease and severe pathology in experimental mouse models. Here, we review the molecular and cellular mechanisms by which OTULIN controls inflammation and discuss the involvement of OTULIN in inflammatory disease development. We also highlight several newly identified roles for OTULIN, including a ubiquitin-independent function.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34074601     DOI: 10.1016/j.it.2021.05.003

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  5 in total

1.  Screening of OTULIN gene mutation with targeted next generation sequencing in Turkish populations and in silico analysis of these mutations.

Authors:  Yüksel Gezgin; Berkay Kırnaz; Afig Berdeli
Journal:  Mol Biol Rep       Date:  2022-03-16       Impact factor: 2.742

Review 2.  Non-proteolytic ubiquitylation in cellular signaling and human disease.

Authors:  Yongrong Liao; Izabela Sumara; Evanthia Pangou
Journal:  Commun Biol       Date:  2022-02-08

3.  Compound heterozygous variants in OTULIN are associated with fulminant atypical late-onset ORAS.

Authors:  Catharina Schuetz; Pamela Fischer-Posovszky; Klaus-Michael Debatin; Julia Zinngrebe; Barbara Moepps; Thomas Monecke; Peter Gierschik; Ferdinand Schlichtig; Thomas F E Barth; Gudrun Strauß; Elena Boldrin; Carsten Posovszky; Ansgar Schulz; Ortraud Beringer; Eva Rieser; Eva-Maria Jacobsen; Myriam Ricarda Lorenz; Klaus Schwarz; Ulrich Pannicke; Henning Walczak; Dierk Niessing
Journal:  EMBO Mol Med       Date:  2022-02-16       Impact factor: 14.260

Review 4.  Disorders of ubiquitylation: unchained inflammation.

Authors:  David B Beck; Achim Werner; Daniel L Kastner; Ivona Aksentijevich
Journal:  Nat Rev Rheumatol       Date:  2022-05-06       Impact factor: 32.286

Review 5.  Molecular and cellular mechanisms in diabetic heart failure: Potential therapeutic targets.

Authors:  Misganaw Asmamaw Mengstie; Endeshaw Chekol Abebe; Awgichew Behaile Teklemariam; Anemut Tilahun Mulu; Assefa Agegnehu Teshome; Edgeit Abebe Zewde; Zelalem Tilahun Muche; Muluken Teshome Azezew
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-02       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.